Under construction – not a live service
Sign in

2024-513299-17-00RecruitingPhase 4

Stopping anti-TNF treatment in Crohn's and Colitis patients in remission

Source: EU CTIS (euclinicaltrials.eu) · Last updated 9 Sept 2024 · Not updated for over 12 months - ask the site whether it is still open

Next steps

Brief summary (registry, in English)

The aim is to identify clinical and biological markers that offer guidance as to which patients successfully may discontinue maintenance anti-TNF treatment, and which patients on the contrary need to continue treatment over an extended period of time in order to remain in remission.

Status (registry)
Recruiting
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
350 (estimated)
First submitted
28 Aug 2024
Start date
5 May 2017
Lead sponsor
Region Skane
EU CT number
2024-513299-17-00
EudraCT number
2016-000235-40

What you commit to

  • Study type: Interventional · Phase 4
  • Planned participants: 350
  • 4 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.

Who cannot take part

Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Corticosteroid (rectal or systemic) or rectal 5-ASA treatment during the last 6 months.
  • For patients with ulcerative colitis: Colonic resection.

Other illness

  • For patients with Crohn's disease: Documented engagement/inflammation of the small bowel proximally of a level of 50 cm from the ileocecal valve. Any examination modality is accepted, and a current/new small intestinal examination is not required. A limited number of small (<5 mm) lesions on capsule endoscopy allowed. Colonic surgery with removal of more than half of the transverse colon.

Other

  • Pregnancy

Who the study is looking for

  • For patients with ulcerative colitis: • Diagnosis: Ulcerative colitis • Age 18-80 years. • Male or female. • IFX or ADA treatment since >12 months; last 3 doses at the same dose and interval. If the patient is on a biosimilar-infliximab the patient must have received at least 3 doses, and at the same dose and interval. • SCCAI score of ≤3. • Endoscopic Baron score of 0-1. The most inflamed part in the rectum/ sigmoid colon is evaluated. A minimum of 40 cm of the colon should be examined.
  • For patients with Crohn's disease: • Diagnosis: Crohn's disease • Age 18-80 years. • Male or female. • IFX or ADA treatment since >12 months; last 3 doses at the same dose and interval. If the patient is on a biosimilar-infliximab the patient must have received at least 3 doses, and at the same dose and interval. • Simplified HBI (sHBI; abdominal palpation excluded) score of ≤4. • Simplified Endoscopic Score for CD (SES-CD) of ≤4 and no ulcer ≥5 mm other than a potential anastomotic ulcer (ie apthous ulcers allowed). • F-calprotectin <200 mg/kg (PhiCal) or <350 mg/kg (Buhlmann).

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on EU CTIS (euclinicaltrials.eu)

Sites (4)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Region Skane Kristianstad Central HospitalKristianstadSwedenRecruiting
Region OestergoetlandLinkopingSwedenRecruiting
Region Skane Skanes UniversitetssjukhusMalmoSwedenRecruiting
Karolinska University HospitalSolnaSwedenRecruiting

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.